Whipplewood Advisors LLC Purchases Shares of 396 Amgen Inc. (NASDAQ:AMGN)

Whipplewood Advisors LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 396 shares of the medical research company’s stock, valued at approximately $103,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. AMF Tjanstepension AB boosted its position in Amgen by 16.9% in the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after buying an additional 17,387 shares during the period. Swedbank AB boosted its position in Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares during the period. Nicholas Hoffman & Company LLC. lifted its position in shares of Amgen by 23.3% during the 3rd quarter. Nicholas Hoffman & Company LLC. now owns 1,033 shares of the medical research company’s stock worth $333,000 after purchasing an additional 195 shares during the last quarter. Diversify Wealth Management LLC lifted its position in shares of Amgen by 26.5% during the 3rd quarter. Diversify Wealth Management LLC now owns 4,647 shares of the medical research company’s stock worth $1,463,000 after purchasing an additional 973 shares during the last quarter. Finally, Cornerstone Wealth Group LLC lifted its position in shares of Amgen by 1.0% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 12,944 shares of the medical research company’s stock worth $4,171,000 after purchasing an additional 130 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AMGN shares. Redburn Partners decreased their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $314.09.

Insider Activity

In other news, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock valued at $20,644,335 over the last quarter. Corporate insiders own 0.69% of the company’s stock.

Amgen Trading Down 0.2 %

NASDAQ AMGN opened at $305.82 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $164.29 billion, a PE ratio of 40.51, a P/E/G ratio of 2.63 and a beta of 0.56. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The firm’s fifty day moving average is $279.97 and its two-hundred day moving average is $300.24.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.11%. Amgen’s payout ratio is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.